Lichter Jay's Form 4 filing
Janux Therapeutics, Inc.JANX · filed Sep 12, 2024
- Accession no.
- 0001415889-24-023337
- Filed
- Sep 12, 2024, 8:42 PM ET
- Trade date
- Sep 10-12, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 9 non-derivative transactions. Open-market sales total $21.2M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lichter JayCIK 0001376355 | 10% Owner |
| Avalon Ventures XI, L.P.CIK 0001652901 | 10% Owner |
| Avalon BioVentures SPV I, L.P.CIK 0001844550 | 10% Owner |
| Avalon BioVentures I, LPCIK 0001873935 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2024 | Common Stock | SSaleDisposed | −11,319 | $46.13F1 | −$522,145.47 | 3,151,532 | Direct | |
| Sep 10, 2024 | Common Stock | SSaleDisposed | −2,193 | $46.13F1 | −$101,163.09 | 610,489 | Indirect | |
| Sep 10, 2024 | Common Stock | SSaleDisposed | −11,557 | $46.13F1 | −$533,124.41 | 3,217,817 | Indirect | |
| Sep 10, 2024 | Common Stock | SSaleDisposed | −34,326 | $46.66F5 | −$1,601,651.16 | 3,117,206 | Direct | |
| Sep 10, 2024 | Common Stock | SSaleDisposed | −6,649 | $46.66F5 | −$310,242.34 | 603,840 | Indirect | |
| Sep 10, 2024 | Common Stock | SSaleDisposed | −35,047 | $46.66F5 | −$1,635,293.02 | 3,182,770 | Indirect | |
| Sep 12, 2024 | Common Stock | SSaleDisposed | −158,031 | $47.00 | −$7,427,457 | 2,959,175 | Direct | |
| Sep 12, 2024 | Common Stock | SSaleDisposed | −30,613 | $47.00 | −$1,438,811 | 573,227 | Indirect | |
| Sep 12, 2024 | Common Stock | SSaleDisposed | −161,356 | $47.00 | −$7,583,732 | 3,021,414 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.50 to $46.47 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Referenced by the price of 3 transactions in Table I.
- F5
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Referenced by the price of 3 transactions in Table I.